EDGAR pro
by EDGAR Online

# MICROPOLIS AI ROBOTICS

## FORM 6-K

(Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16)

Filed 11/23/26 for the Period Ending 11/23/26

| | |
|---|---|
| Telephone | 0097142767008 |
| CIK | 0001993431 |
| Symbol | MCRP |
| SIC Code | 3714 - Motor Vehicle Parts and Accessories |
| Industry | Industrial Machinery & Equipment |
| Sector | Industrials |
| Fiscal Year | 12/31 |

Powered By EDGAR Online
https://www.edgar-online.com
© Copyright 2026, EDGAR Online LLC, a subsidiary of OTC Markets Group. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online LLC, a subsidiary of OTC Markets Group, Terms of Use.

**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**
**PURSUANT TO RULE 13a-16 OR 15d-16**
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2026**

**Commission File Number: 001-42550**

**Micropolis AI Robotics**
**(Registrant's Name)**

**Warehouse 1, Dar Alkhaleej Building**
**Dubai Production City, Dubai, UAE**
**(Address of Principal Executive Offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

## INFORMATION CONTAINED IN THIS FORM 6-K REPORT

**NYSE American Acceptance of Extension Request to Regain Compliance with Continued Listing Standards**

As previously disclosed in the Report on Form 6-K furnished by Micropolis AI Robotics (the "Company" or "Micropolis") to the Securities and Exchange Commission (the "SEC") on May 19, 2026, the Company received a notice from NYSE Regulation on May 18, 2026. The notice indicated that the Company is not in compliance with the continued listing standards of NYSE American LLC ("NYSE American" or the "Exchange") because it failed to timely file its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "2025 Form 20-F") by the filing due date of May 15, 2026 (the "Filing Delinquency"). Pursuant to Section 1007 of the NYSE American Company Guide (the "Company Guide"), the Company was afforded an initial six-month cure period through November 15, 2026 (the "Initial Cure Period").

On November 10, 2026, the Company submitted an extension request to the Exchange. On November 11, 2026, the Company received a letter from NYSE Regulation (the "Extension Letter") stating that it had reviewed and determined to accept the Company's extension request. The Extension Letter granted the Company a plan period through December 13, 2026 (the "New Cure Deadline") to file the 2025 Form 20-F and any subsequently delayed filings with the SEC.

The Company remains out of compliance with Sections 134 and 1101 of the Company Guide as a result of the Filing Delinquency, and its listing on NYSE American is being continued pursuant to the extension. During the plan period, NYSE Regulation staff will periodically review the Company's adherence to the milestones in its plan. The Extension Letter has no immediate impact on the listing of the Company's ordinary shares. The shares will continue to be listed and traded on NYSE American during the plan period, subject to the Company's adherence to its plan and its continued compliance with the other listing requirements of NYSE American.

The Company is working diligently with its auditors and advisors to complete the 2025 Form 20-F and intends to file it on or before the New Cure Deadline. However, there can be no assurance that the Company will file by the New Cure Deadline or that it will ultimately regain compliance with all applicable Exchange listing standards.

On November 23, 2026, the Company issued a press release pursuant to Sections 402 and 1009(e) of the Company Guide announcing receipt of the Extension Letter. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Safe Harbor Statement**

Certain statements made in this report on Form 6-K are "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this report, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: the Company's ability to complete the audit of its financial statements and file the 2025 Form 20-F and any subsequently delayed filings by the New Cure Deadline or within the maximum cure period; the Company's ability to regain and maintain compliance with NYSE American continued listing standards; the ability to manage growth; the ability to identify and integrate other future acquisitions; the ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting the Company's profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; and a pandemic or epidemic. The forward-looking statements contained in this report are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this report.

**EXHIBIT INDEX**

| Exhibit No. | Description |
|---|---|
| 99.1 | Press release of the Company, dated November 23, 2026 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Micropolis AI Robotics**

Date: November 23, 2026

By: */s/ Fareed Aljawhari*
Name: Fareed Aljawhari
Title: Chief Executive Officer and Director

**Exhibit 99.1**

**Micropolis Receives Extension from NYSE American to File Delayed Annual Report**

Dubai, UAE, Nov. 23, 2026 (GLOBE NEWSWIRE) -- Micropolis AI Robotics (NYSE American: MCRP) ("Micropolis" or the "Company") today announced that on November 11, 2026 it received a letter from NYSE Regulation accepting the Company's request for an extension to regain compliance with the continued listing standards of NYSE American LLC ("NYSE American" or the "Exchange"). NYSE Regulation granted the Company a plan period through December 13, 2026 (the "New Cure Deadline") to file its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "2025 Form 20-F") and any subsequently delayed filings with the Securities and Exchange Commission (the "SEC").

As previously announced on May 19, 2026, the Company is not in compliance with NYSE American's continued listing standards because it failed to timely file the 2025 Form 20-F by the filing due date of May 15, 2026 (the "Filing Delinquency"). The Company remains out of compliance with Sections 134 and 1101 of the NYSE American Company Guide (the "Company Guide"), and its listing on NYSE American is being continued pursuant to an extension.

Under Section 1007 of the Company Guide, the Company had an initial six-month cure period through November 15, 2026. As the Company was unable to cure the Filing Delinquency within that period, it submitted an extension request to the Exchange on November 10, 2026, which NYSE Regulation reviewed and accepted.

During the plan period, NYSE Regulation staff will periodically review the Company's adherence to the milestones in its plan. Exchange staff will initiate delisting proceedings as appropriate if the Company does not make progress consistent with the plan during the plan period. The same applies if the Company does not file the 2025 Form 20-F and any subsequently delayed filings by May 15, 2027, the end of the maximum 12-month cure period. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.

The letter has no immediate impact on the listing of the Company's ordinary shares. The shares will continue to be listed and traded on NYSE American during the plan period, subject to the Company's adherence to its plan and its continued compliance with the other listing requirements of NYSE American.

The Company is working diligently with its auditors and advisors to complete the 2025 Form 20-F and intends to file it on or before the New Cure Deadline. However, there can be no assurance that the Company will file the 2025 Form 20-F by the New Cure Deadline or that it will ultimately regain compliance with all applicable Exchange listing standards.

This announcement is made in compliance with Sections 402 and 1009(e) of the Company Guide.

**About Micropolis AI Robotics**

Micropolis is a robotics manufacturer founded in 2014, based in UAE with its headquarters located in Dubai Production City, Dubai, UAE. It specializes in developing AMRs that utilize wheeled EV platforms and are equipped with autonomous driving capabilities. As part of Micropolis' product offerings, it integrates application-specific pods that serve as the primary purpose of a robot. These pods are designed to accommodate various functionalities, including surveillance cameras, road sweepers, logistics compartments, as well as collaborative robots (cobots) intended for direct human-robot interaction.

**Forward-Looking Statements**

Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: the Company's ability to complete the audit of its financial statements and file the 2025 Form 20-F and any subsequently delayed filings by the New Cure Deadline or within the maximum cure period; the Company's ability to regain and maintain compliance with NYSE American continued listing standards; the ability to manage growth; the ability to identify and integrate other future acquisitions; the ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting the Company's profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; and a pandemic or epidemic. The forward-looking statements contained in this release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release.

**Contact Information**

For Investor Relations:
Micropolis AI Robotics
Email: Francesca@micropolis.ae